Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-1-antitrypsin modified process - Grifols

Drug Profile

Alpha-1-antitrypsin modified process - Grifols

Alternative Names: Alpha-1 MP - Grifols; Alpha-1 proteinase-inhibitor-modified process - Grifols; Alpha-1-antitrypsin IV - Grifols; Alpha-1-protease-inhibitor-modified process - Grifols; Alpha-antitrypsin modified process - Grifols; Alpha1-PI; Prolastin; Prolastin-C; Prolastin-C Liquid; TAL 6004

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Grifols; Vifor Pharma
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II Chronic fatigue syndrome; Type 1 diabetes mellitus

Most Recent Events

  • 10 Jan 2018 Grifols prematurely terminates a phase II trial in Chronic fatigue syndrome (In adults, In the elderly) in Spain (EudraCT2014-002007-13)
  • 25 Oct 2017 Grifols Therapeutics terminates a phase II trial for Type-1 diabetes mellitus (Newly-diagnosed, In children, In adolescents, In adults) in USA as week 52 primary endpoint results would be unaffected by follow-up data prior to week 104 (NCT02093221)
  • 22 Sep 2017 Registered for Alpha 1-antitrypsin deficiency in USA (IV, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top